- Home
- MURA
MURA
Mural Oncology plc
as 11-19-2025 3:59pm EST
Stocks
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
| Founded: | 2013 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 36.0M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 112.3K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $4.74 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mural Oncology plc (MURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Goodman Vicki L | MURA | Chief Medical Officer | Nov 10 '25 | Sell | $2.08 | 5,036 | $10,474.88 | 84,727 | |
| Cutler Adam D. | MURA | Chief Financial Officer | Nov 3 '25 | Sell | $2.09 | 7,148 | $14,939.32 | 99,290 |
Latest Mural Oncology plc News
MURA Breaking Stock News: Dive into MURA Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Form 8.3
Business Wire
6 days ago
Form 8.3
Business Wire
8 days ago
Form 8.3
GlobeNewswire
8 days ago
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Business Wire
10 days ago
Form 8.3
Business Wire
13 days ago
Form 8.3
Business Wire
20 days ago
Form 8.3 - Mural Oncology plc
MT Newswires
a month ago
Mural Oncology Shareholders Approve $36.2 Million Sale to XOMA Royalty Unit
Compare MURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MURA Mural Oncology plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.